BNP Paribas Asset Management
MYGN icon

BNP Paribas Asset Management’s Myriad Genetics MYGN Stock Holding History

BNP Paribas Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,437
Closed -$15.5K – 2317
2026
Q1 		$15.5K Buy
3,437
+1,577
+85% +$8.22K ﹤0.01% 2097
2025
Q4 		$11K Buy
1,860
+649
+54% +$4.71K ﹤0.01% 2123
2025
Q3 		$9K Hold
1,211
– – ﹤0.01% 1672
2025
Q2 		$6K Buy
+1,211
New +$7.15K ﹤0.01% 1947

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management's MYGN Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 3,437 shares — an estimated $15.5K sold.

BNP Paribas Asset Management first reported a position in MYGN in Q2 2025 and held it in 4 quarters. The position peaked at $15.5K in Q1 2026. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 3,437 Myriad Genetics shares in Q2 2026, an estimated $15.5K.
  • BNP Paribas Asset Management first reported a position in Myriad Genetics in Q2 2025 and held it in 4 quarters.
  • BNP Paribas Asset Management's Myriad Genetics position peaked at $15.5K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.